Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scripps Research Institute Study Shows MicroRNAs Can Trigger Lymphomas

09.08.2013
A small group of immune-regulating molecules, when overproduced even moderately, can trigger the blood cancers known as lymphomas, according to a new study led by scientists from The Scripps Research Institute (TSRI).

The six “microRNA” molecules were already known to be overproduced in lymphomas and in many other human cancers, but no one had demonstrated that they can be the prime cause of such cancers—until now. The new study also identified the major biological pathways through which these microRNAs ignite and maintain cancerous growth.

“We were able to show how this microRNA cluster can be the main driver of cancer, and so we now can start to think about therapies to combat its effects,” said TSRI Assistant Professor Changchun Xiao. Xiao was the senior investigator for the study, which appeared this week in an advance online version of the EMBO Journal, a publication of the European Molecular Biology Organization.

‘Dimmer Switches’

Discovered only in the 1990s, microRNAs are short molecules that work within virtually all animal and plant cells. Typically each one functions as a “dimmer switch” for one or more genes; it binds to the transcripts of those genes and effectively keeps them from being translated into proteins. In this way microRNAs can regulate a wide variety of cellular processes.

The focus of the new study was a cluster of six microRNAs known as miR-17~92, encoded by a single gene on chromosome 13. Studies of miR-17~92, including one from Xiao’s lab earlier this year, have shown that it controls various immune-related and developmental processes, depending on the type of cell in which it is expressed.

But the miR-17~92 cluster is best known as a suspected cause of cancers, so much so that it has been dubbed “oncomir-1.” Since 2005, scientists have found the cluster to be overproduced in lymphomas, leukemias, brain cancers, breast cancers, prostate cancers and other tumor types. It appears to play an especially prominent role in lymphomas. In a study reported last year, National Cancer Institute researchers found a drastic overexpression of the miR-17~92 cluster in every tumor they sampled from patients with a common type of non-Hodgkin’s lymphoma called Burkitt lymphoma.

Researchers have found evidence that this overexpression of miR-17~92 isn’t merely an incidental result of cancerous change in cells; it also works to speed up cancerous growth. “What hasn’t been known is whether miR-17~92 can be the primary trigger of such cancers,” said Xiao.

Identifying a Primary Trigger for Cancer

In the new study, he and his colleagues demonstrated that it can be. The project started with a colony of genetically engineered mice that Xiao established several years ago, while doing postdoctoral research in the laboratory of renowned immunologist Klaus Rajewsky at Harvard Medical School. “The mice contain an artificial gene segment that we can activate to overproduce miR-17~92 in any chosen cell type,” explained Xiao. In this case, the overproduction occurs only in antibody-producing immune cells called B cells—the same cells from which Burkitt lymphoma originates.

After moving to TSRI to set up his own laboratory in 2008, Xiao expanded this transgenic mouse colony and began to gather data on it. “We found that 80 percent of these mice develop lymphomas within one year,” said Hyun-Yong Jin, a graduate student in the Xiao laboratory who was a lead author of the new study.

“It was striking that this very high rate of lymphoma came from only a three-to-fivefold overexpression of miR-17~92 in B cells, whereas human Burkitt lymphomas typically show more than tenfold overexpression,” Xiao said.

Having established that miR-17~92 overexpression can powerfully trigger B cell lymphomas, Xiao and his colleagues looked at this microRNA cluster’s role in a standard mouse model of Burkitt lymphoma. The B cells of these mice are engineered to overexpress a cancer-inducing “oncogene” called myc, whose hyperactivity—a characteristic of human Burkitt lymphoma cases—triggers a number of abnormalities, including the overproduction of miR-17~92.

The miR-17~92 overproduction turned out to be crucial for the development of these lymphomas. “Deleting miR-17~92 from the B cells of these mice significantly delayed the development of lymphomas and extended the mice’s survival,” said Maoyi Lai, a research associate in the Xiao laboratory who was a lead author of the study with Hiroyo Oda, a research associate in the Xiao laboratory during the study and now a member of the National Center for Global Health and Medicine in Chiba, Japan. “Looking more closely, we found that the lymphomas that did develop in these mice originated only from B cells in which miR-17~92 had managed to escape deletion and was still being overproduced.”

Taking Off the Brakes

The next step was to investigate how miR-17~92 triggers cancer so powerfully. Using a new technique for finding the binding sites of microRNAs on messenger RNAs, Xiao’s collaborator Bryan R. Cullen and colleagues at the Duke University School of Medicine identified hundreds of genes that miR-17~92 works to suppress. A large fraction of these turned out to be genes that normally keep the brakes on cell growth and survival programs. By suppressing these braking genes, miR-17~92 ends up strongly promoting cell growth and survival. “It affects so many important pathways that even a modest miR-17~92 overexpression apparently moves the cell from a normal growth and survival mode into the cancerous state,” Xiao said.

Xiao’s team demonstrated the importance of two of these growth/survival pathways by injecting chemical inhibitors of the pathways into mice with miR-17~92-driven lymphomas. “Each inhibitor shrank the tumors and prolonged mouse survival,” said Xiao. “We’re now studying the effect of combining inhibitors of these miR-17~92-driven cancer pathways and possibly targeting miR-17~92 microRNAs directly.”

Contributors to the study, “MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways,” included Bryan R. Cullen and his postdoctoral fellow Rebecca L. Skalsky at Duke University School of Medicine; Klaus Rajewsky of Harvard Medical School (now at the Max Delbrück Center for Molecular Medicine in Berlin); Kelly Bethel of Scripps Clinic in La Jolla, CA, who performed the pathology studies of mouse lymphomas; and Jovan Shepherd, Seung Goo Kang, Wen-Hsien Liu and Mohsen Sabouri-Ghomi of the Xiao laboratory at TSRI. For more information on the paper, see http://www.nature.com/emboj/journal/vaop/ncurrent/full/emboj2013178a.html

The study was funded by the PEW Charitable Trusts, the Cancer Research Institute, and the National Institutes of Health (R01 AI067968, R01 AI087634 and RC1 CA146299).

About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8136
press@scripps.edu

Mika Ono | EurekAlert!
Further information:
http://www.scripps.edu

More articles from Life Sciences:

nachricht New way to look at cell membranes could change the way we study disease
19.11.2018 | University of Oxford

nachricht Controlling organ growth with light
19.11.2018 | European Molecular Biology Laboratory

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

New materials: Growing polymer pelts

19.11.2018 | Materials Sciences

Earthquake researchers finalists for supercomputing prize

19.11.2018 | Information Technology

Controlling organ growth with light

19.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>